Fairvalue-Calculator Fairvalue-Calculator
EN DE

Forte Biosciences, Inc (FBRX) Fair Value & Analysis

Healthcare · US · Market cap $366M

Price$18.15
Fair Value$13.40
Upside-26.2%
Quality95/100
Evidence: Low Range $10.05 – $16.75

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Forte Biosciences, Inc (FBRX) currently trades at $18.15, while our model-based Fair Value estimate is $13.40 — implying the stock looks roughly 26.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Forte Biosciences, Inc (FBRX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $13.40 versus a price of $18.15 — about −26% (overvalued). Model-based estimate, not financial advice.
What is the fair value of FBRX?
Our 21-model fair value for Forte Biosciences, Inc is $13.40 (as of Jun 24, 2026), built from audited fundamentals. The current price is $18.15.
What is the quality score of FBRX?
Forte Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.